Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multimedia
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Pertussis Treatment Market Projected to Hit US$ 5.3 Billion by 2034, with a 3.4% CAGR | Fact.MR Report


News provided by

Fact.MR

31 Jul, 2024, 10:45 GMT

Share this article

Share toX

Share this article

Share toX

Pertussis Medications and Vaccinations Leading Therapeutic Approaches Driving Stance of Companies in the Market.

ROCKVILLE, Md., July 31, 2024 /PRNewswire/ -- The global Pertussis Treatment Market is estimated at a value of US$ 3.8 billion in 2024 and is forecasted to increase to US$ 5.3 billion by the end of 2034, reveals Fact.MR, a market research and competitive intelligence provider, in its new research report.

Pertussis, also known as whooping cough, is an infectious respiratory disease caused by the Bordetella pertussis bacteria. Pertussis mostly affects young children and the older population, and treatment involves medication, vaccination, and supportive care.

Rising prevalence of whooping cough caused by different factors is leading to a high demand for innovative and effective pertussis therapeutic solutions. Drug manufacturers are focused on developing new antibiotics and treatment protocols to combat Bordetella pertussis bacteria. For the same, industry giants are heavily investing in research and development efforts. Targeted antibiotic therapies are the frontline treatments for pertussis infection.

Researchers worldwide are also exploring novel antibiotic classes that can demonstrate efficacy against the Bordetella pertussis bacteria. Combination therapies are expected to offer enhanced treatment outcomes and reduce the likelihood of resistance. Furthermore, the personalized medication trend is also set to offer lucrative growth opportunities for key companies that are involved in providing pertussis treatment solutions.

For More Insights into the Market, Request a Sample of this Report: 
https://www.factmr.com/connectus/sample?flag=S&rep_id=10267 

Key Takeaways from the Pertussis Treatment Market Study:

  • Global demand for pertussis therapeutic solutions is projected to rise at a CAGR of 3.4 from 2024 to 2034.
  • The market for pertussis treatment in the United States is forecasted at a value of US$ 1.29 billion in 2024.
  • Sales of pertussis drugs in South Korea are forecasted to rise at a CAGR of 3.7% through 2034.
  • The market for pertussis medications is estimated at US$ 1.59 billion in 2024.
  • Hospital pharmacies are projected to capture 39.1% of the global market share by 2034.

"North America, followed by Western Europe, will be key regional markets for pertussis treatment over the next decade," says a Fact.MR analyst.

Leading Players Driving Innovation in the Pertussis Treatment Market:

Key participants in the pertussis treatment industry are Johnson & Johnson Services Inc.; GlaxoSmithKline, Plc.; Merck & Co. Inc.; Sanofi; Pfizer Inc.; Novartis AG; Panacea Biotech; China National Biotec Group; Changchun Changsheng Life Sciences; Daiichi Sankyo Company Ltd.; Mylan NV; Boehringer Ingelheim International GmbH; Bristol Myers Squibb Company; Mitsubishi Tanabe Pharma; Astellas Pharma; Shenzhen KangTai Biological Products.

Collaborations Key Trend in the Pertussis Treatment Market:

Pharmaceutical companies, research institutions, and government healthcare organizations are collaborating for the development and discovery of advanced pertussis medications. These collaborations are aimed at becoming more effective in reducing the ill effects of pertussis and boosting the profits of several stakeholders. International agreements are aimed at the more effective addressing and managing of pertussis globally. These are expected to increase the sales of pertussis therapeutic solutions, especially in high-potential markets such as Latin America and Asia Pacific.

According to an article under scientific reports published by Nature on 16th March 2023, a pangenome approach-based loop-mediated isothermal amplification assay is proving effective for specific and early detection of pertussis infection.

Pertussis Treatment Industry News:

On 25 March 2024, As per a press release by EurekAlert, researchers from the American Society for Biochemistry and Molecular Biology uncovered a key biomolecule involved in pertussis infection. The discovery is expected to aid in creating a new drug or vaccine for whooping cough.

Get Customization on this Report for Specific Research Solutions: 
https://www.factmr.com/connectus/sample?flag=S&rep_id=10267

Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Type:

  • Medications
  • Vaccinations
  • Supportive Treatments

Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Diagnosis:

  • Blood Tests
  • Chest X-Rays
  • Nose or Throat Culture & Tests

Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Mode of Purchase:

  • Rx
  • OTC

Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration:

  • Oral
  • Parenteral

Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel:

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Disease Stage:

  • Incubation Stage
  • Catarrhal Stage
  • Paroxysmal Stage
  • Convalescent Stage

More Valuable Insights:

Fact.MR, in its new offering, presents an unbiased analysis of the global pertussis treatment market, presenting historical demand data (2019 to 2023) and forecast statistics for the period (2024 to 2034).

The study divulges essential insights on the market-based treatment type (medications, vaccinations, supportive treatments, others), diagnosis (blood tests, chest X-rays, nose or throat culture & tests), mode of purchase (Rx, OTC), route of administration (oral, parenteral, others), disease stage (incubation stage, catarrhal stage, paroxysmal stage, convalescent stage), and distribution channel (hospital pharmacies, online pharmacies, retail pharmacies), across seven major regions of the world (North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia & Pacific, and MEA).

Check out More Related Studies Published by Fact.MR Research: 

Psychotic Disorder Treatment Market accounts for US$ 13.6 billion and is projected to surge past a valuation of US$ 24.5 billion by the end of 2032.

Alexandrite Laser Treatment Market is calculated at US$ 48.7 million for 2024 and is forecasted to reach US$ 83.2 million by 2034, advancing at a CAGR of 5.5%.

Achalasia Treatment Market Statistics by Treatment (Non-Surgical Treatment, Botulinum Toxin Type A, Pneumatic Dilation, Surgical Treatment, Peroral Endoscopic Myotomy (POEM), Heller Myotomy) & By End User- Global Review 2018 To 2028.

Lewy Body Dementia Treatment Market is predicted to expand steadily at 6% CAGR and reach US$ 8.45 billion by the end of 2033.

Antibiotic-Associated Diarrhea Treatment Market Forecast, Trend Analysis & Competition Tracking - Global Review 2018 to 2028

Bell's Palsy Treatment Market by Drug Class (Corticosteroids, Anticonvulsants, Antibacterial, Antivirals), Based on Distribution Channel (Hospital, Retail, Drug Stores, Online) - Global Insights to 2028.

About Us: 

Fact.MR is a distinguished market research company renowned for its comprehensive market reports and invaluable business insights. As a prominent player in business intelligence, we deliver deep analysis, uncovering market trends, growth paths, and competitive landscapes. Renowned for its commitment to accuracy and reliability, we empower businesses with crucial data and strategic recommendations, facilitating informed decision-making and enhancing market positioning.

With its unwavering dedication to providing reliable market intelligence, FACT.MR continues to assist companies in navigating dynamic market challenges with confidence and achieving long-term success. With a global presence and a team of experienced analysts, FACT.MR ensures its clients receive actionable insights to capitalize on emerging opportunities and stay ahead in the competitive landscape.  

Contact:  
11140 Rockville Pike  
Suite 400  
Rockville, MD 20852  
United States  
Tel: +1 (628) 251-1583  
Sales Team: sales@factmr.com   
Follow Us: LinkedIn | Twitter | Blog 

Modal title

Also from this source

Bisabolene Market is Forecasted to Reach US$ 4.6 Million by 2034, Expanding at a CAGR of 3.9% | Fact.MR Report

According to a new research report published by Fact.MR, the global Bisabolene Market was valued at US$ 3 million in 2023 and has been forecasted to...

Hyaluronic Acid Raw Material Market is projected to grow at a CAGR of 5.2%, Reaching a value of $11.7 billion by 2034 | Fact.MR Report

The global Hyaluronic Acid Raw Material Market has been valued at US$ 7.05 billion in 2024, as stated in the recently updated industry analysis by...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

Pharmaceuticals

Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.